RxDoctor Payments Data

Stephen Greenspan, MD

Internal Medicine · Philadelphia, PANPI 1255366845

Payments from drug & device makers

$365in general payments, 2019–2025

Across 19 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$79
  • Novo Nordisk$63
  • Merck$46
  • Johnson & Johnson$33
  • Boston Scientific$33
  • Cranial Technologies, Inc$30
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,526
Medicare patients
132
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$64,989
XareltoRivaroxaban33$29,211
JardianceEmpagliflozin31$27,333
MounjaroTirzepatide18$18,268
TradjentaLinagliptin24$14,803
PentasaMesalamine12$8,023
Breo ElliptaFluticasone/Vilanterol13$6,905
VyvanseLisdexamfetamine Dimesylate14$5,261
Levothyroxine Sodium125$3,746
Varenicline Tartrate11$3,341
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,145
Testosterone12$2,431
Rosuvastatin Calcium107$2,194
Albuterol Sulfate HfaAlbuterol Sulfate63$2,118
Tamsulosin Hcl59$1,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$63$64,98962 claims
Johnson & JohnsonXarelto$33$29,21133 claims
GSKBreo Ellipta$79$6,90513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →